UNSPSC 51286701: Aditoprim

This classification denotes a dihydrofolate reductase inhibitor and anti-infective agent with the molecular formula C15H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z81WDX2ZH, chemically known as 2,4-pyrimidinediamine, 5-((4-(dimethylamino)-3,5-dimethoxyphenyl)methyl)- but more generally known as aditoprim, which bears US NIH Compound Identifier 68755. European Medicines Agency schedules Aditoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05275MIG.

The term ADITOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). ADITOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(N(C)C)C(OC)CC(CC2C(NC(NC2)N)N)C1)C.

UNSPSC 51286701 Aditoprim is a Commodity code capturing pharmaceutical and medical supply procurement by state and local health agencies, though the recent solicitation activity under this code reveals a significant mismatch: the code's nominal scope does not align with what state and local governments are actually buying. The recent opportunities span naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for fire rescue operations (City of Tampa), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). These solicitations reflect a broad range of pharmaceutical, medical supply, and emergency response product procurement rather than a single defined commodity. Issuing bodies include county health departments, state health commissions, municipal fire departments, and cooperative purchasing consortia serving multiple jurisdictions. The scope of work encompasses emergency medical supplies, naloxone for opioid-response programs, commodity-level pharmaceutical products, and OTC consumables.

Activity under this code appears concentrated in Florida, Texas, Minnesota, and Oregon, with representation across county-level, state-level, and municipal buyers. Recent opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023); the City of Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000, with a 5 percent Small Local Business Enterprise discount and responses due March 13, 2026; the Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescriptions (response deadline April 3, 2026); and the Minnesota Department of Administration's cooperative purchasing RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (responses due March 26, 2026). The mismatch between the code's nominal scope and actual procurement activity suggests the code may not accurately reflect current state and local buying patterns in pharmaceutical and medical supply categories.